GSK PLC-SPON ADR (GSK) Stock Institutional Trading Activity


GSK PLC-SPON ADR (GSK) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Causeway Capital Management, Renaissance Technologies LLC, Kahn Brothers Group, Hancock Classic Value, and Dodge & Cox Stock Fund. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q3 2022Hillman Value FundBuy243,978243,978$7,181
Q3 2022Renaissance Technologies LLCBuy9,354,0579,354,057$275,290
Q3 2022Dodge & Cox Stock FundBuy58,583,98958,583,989$1,724,127
Q2 2022Causeway Capital ManagementBuy258,163258,163$11,238

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.